That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients. Results of the trial were presented at the 2021 ASCO GI Cancer Symposium. Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2, a vascular…
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Researchers are using IORT–intraoperative radiation therapy–to treat pancreatic cancer that cannot be surgically removed.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.